This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 is a Highly Potent
Therapeutic Agent in Multiple Preclinical Cancer Models
Pia M. Challita-Eid1*, Daulet Satpayev2, Peng Yang1, Zili An1, Karen Morrison1, Yuriy Shostak1,
Arthur Raitano1, Rossana Nadell1, Wendy Liu1, Dawn Ratay Lortie1, Linnette Capo1, Alla
Verlinsky1, Monica Leavitt1, Faisal Malik1, Hector Aviña1, Claudia I. Guevara1, Nick Dinh1, Sher
Karki1, Banmeet S. Anand1, Daniel S. Pereira1, Ingrid B. J. Joseph1, Fernando Doñate1, Kendall
Morrison1, David R. Stover1
1Agensys Inc., Santa Monica, CA
2Previously at Agensys, Inc.; currently at ImaginAb, Inglewood, CA
All authors worked at Agensys Inc. during the period of the study.
*Corresponding author: Pia M. Challita-Eid, Agensys, Inc., 1800 Stewart Street, Santa Monica, CA 90404; Phone: (424) 280-5000; Email: [email protected]
Financial support, including the source and number of grants, for each author: Funded by Agensys, Inc., an affiliate of Astellas Pharma, Inc.
Disclosure of Potential Conflicts of Interest: All authors are/were employees of Agensys, Inc., an affiliate of Astellas Pharma, Inc., during the period of the study.
Running title: ADC cancer therapeutic targeting nectin-4
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30. 2. Nadal R, Bellmunt J. New treatments for bladder cancer: when will we make progress? Curr Treat
Options Oncol 2014;15(1):99-114. 3. Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ. Emerging therapeutic targets
in bladder cancer. Cancer Treat Rev 2014. 4. Beck A, Reichert JM. Antibody-drug conjugates: present and future. MAbs 2014;6(1):15-7. 5. Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov
2013;12(5):329-32. 6. Younes A. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma. Hematol
Oncol Clin North Am 2014;28(1):27-32. 7. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-
positive advanced breast cancer. N Engl J Med 2012;367(19):1783-91. 8. Dhillon S. Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced
breast cancer previously treated with trastuzumab-based therapy. Drugs 2014;74(6):675-86. 9. Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, et al. FDA approval: ado-
trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res 2014;20(17):4436-41.
10. Samanta D, Almo SC. Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity. Cell Mol Life Sci 2014.
11. Mori M, Rikitake Y, Mandai K, Takai Y. Roles of nectins and nectin-like molecules in the nervous system. Adv Neurobiol 2014;8:91-116.
12. Rikitake Y, Mandai K, Takai Y. The role of nectins in different types of cell-cell adhesion. J Cell Sci 2012;125(Pt 16):3713-22.
13. Blackwood EM, Lugo TG, Kretzner L, King MW, Street AJ, Witte ON, et al. Functional analysis of the AUG- and CUG-initiated forms of the c-Myc protein. Mol Biol Cell 1994;5(5):597-609.
14. Green LL. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999;231(1-2):11-23.
15. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21(7):778-84.
16. Sussman D, Smith LM, Anderson ME, Duniho S, Hunter JH, Kostner H, et al. SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer. Mol Cancer Ther 2014;13(12):2991-3000.
17. Mattie M, Christensen A, Chang MS, Yeh W, Said S, Shostak Y, et al. Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. Neoplasia 2013;15(10):1138-50.
18. Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 1999;96(25):14523-8.
19. Reymond N, Fabre S, Lecocq E, Adelaide J, Dubreuil P, Lopez M. Nectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction. J Biol Chem 2001;276(46):43205-15.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
20. Fabre S, Reymond N, Cocchi F, Menotti L, Dubreuil P, Campadelli-Fiume G, et al. Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin 4 bind to the predicted C-C'-C"-D beta-strands of the nectin1 V domain. J Biol Chem 2002;277(30):27006-13.
21. Delpeut S, Noyce RS, Richardson CD. The tumor-associated marker, PVRL4 (nectin-4), is the epithelial receptor for morbilliviruses. Viruses 2014;6(6):2268-86.
22. Muhlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, Leonard VH, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011;480(7378):530-3.
23. Athanassiadou AM, Patsouris E, Tsipis A, Gonidi M, Athanassiadou P. The significance of Survivin and Nectin-4 expression in the prognosis of breast carcinoma. Folia Histochem Cytobiol 2011;49(1):26-33.
24. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K, et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 2009;69(16):6694-703.
25. Fabre-Lafay S, Monville F, Garrido-Urbani S, Berruyer-Pouyet C, Ginestier C, Reymond N, et al. Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer 2007;7:73.
26. Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, et al. Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol 2010;134(5):835-45.
27. Rupp U, Schoendorf-Holland E, Eichbaum M, Schuetz F, Lauschner I, Schmidt P, et al. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs 2007;18(4):477-85.
28. Wilken JA, Perez-Torres M, Nieves-Alicea R, Cora EM, Christensen TA, Baron AT, et al. Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab. Biochemistry 2013;52(26):4531-40.
29. Lam L, McAndrew N, Yee M, Fu T, Tchou JC, Zhang H. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta 2012;1826(1):199-208.
30. Tse C, Gauchez AS, Jacot W, Lamy PJ. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev 2012;38(2):133-42.
31. Ghedini GC, Ciravolo V, Tortoreto M, Giuffre S, Bianchi F, Campiglio M, et al. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility. J Cell Physiol 2010;225(1):256-65.
32. Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol 2009;27(10):1685-93.
33. Pavlova NN, Pallasch C, Elia AE, Braun CJ, Westbrook TF, Hemann M, et al. A role for PVRL4-driven cell-cell interactions in tumorigenesis. Elife 2013;2:e00358.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313
Published OnlineFirst March 24, 2016.Cancer Res Pia M. Challita-Eid, Daulet Satpayev, Peng Yang, et al. Preclinical Cancer ModelsNectin-4 is a Highly Potent Therapeutic Agent in Multiple Enfortumab Vedotin Antibody-Drug Conjugate Targeting
Updated version
10.1158/0008-5472.CAN-15-1313doi:
Access the most recent version of this article at:
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerres.aacrjournals.org/content/early/2016/03/24/0008-5472.CAN-15-1313To request permission to re-use all or part of this article, use this link
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 24, 2016; DOI: 10.1158/0008-5472.CAN-15-1313